Several monoclonal antibodies were produced against the human T lymphocyte leukemia cell line HSB-2 by fusing spleen cells from hyperimmune mice with NS-1 myeloma cells. One clone, designated TA-1, was initially characterized for reactivity with normal and leukemic human hematopoietic cells. Using indirect immunofluorescence, TA-1 was shown to bind to ~75% of peripheral blood lymphocytes. Enrichment for T and B lymphocytes followed by double fluorochrome labeling studies revealed that most if not all E+ T lymphocytes and ~10% of B lymphocytes were TA-1+. TA-1 also reacted with ~67% of thymocytes, mixed lymphocyte culture-activated T lymphocytes, the entire peripheral blood monocyte population, and ~13% of nucleated bone marrow cells. TA-1+ cells in bone marrow included both phagocytic and nonphagocytic cells. TA-1 did not bind to peripheral blood granulocytes, red blood cells, or platelets. Studies of acute lymphoblastic leukemia (ALL) revealed that 6 of 11 T-ALL and 1 of 21 E-, SIg--ALL were TA-1+, whereas cells from 10 patients with chronic lymphocytic leukemia were TA-1-. Interestingly, TA-1 was able to distinguish acute myelomonocytic leukemic cells (TA-1+) from acute myelocytic leukemic cells (TA-1-). In summary, these studies demonstrate the existence of a determinant recognized by TA-1 that is primarily expressed on cells of T lymphocyte and monocyte/macrophage lineage.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of Immunology|
|State||Published - 1980|